The purpose of this study is to compare a usual maintenance treatment for multiple myeloma (lenalidomide) to using the study drug (daratumumab/rHuPH20) plus the usual treatment. We want to learn if the addition of daratumumab/rHuPH20 to the usual treatment could help you live longer after your stem cell transplant. This study will help the study doctors find out if this different approach is better than the usual approach.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
North Carolina (Statewide)
Sascha Tuchman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Multiple Myeloma)
Transplant
19-2598
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
